N/A N=127 Iron Treatment for Young Children With Non-anemic Iron Deficiency
Non-anemic Iron Deficiency
Primary: Early Learning Composite (ELC) From the Mullen Scales of Early Learning — 113.0; 113.5; 110.48; 107.94 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=251 Nutritional Education and the Prevention of Iron Depletion in Children 9 Months to 2 Years
Iron Deficiency
Primary: The Primary Outcome is Iron Depletion, and Will be Defined as Serum Ferritin <10 mcg/L. — 64; 71; 13; 10 participants — p=0.42
Phase 4 N=88 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate
Ulcerative Colitis · Crohn's Disease
Primary: Mean Change in Haemoglobin Concentration. — 1.22; 1.30 g/dl — p=0.23
Phase 3 N=1 Oral Iron Versus Oral Iron Plus a Web-based Behavioral Intervention in Young Children (IRONCHILD)
Iron Deficiency Anemia · Iron-deficiency
Primary: Percentage of Eligible Patients Enrolled — 1; 0 Participants
Phase 3 N=402 Sub-clinical Inflammation and Iron Supplementation
Anemia
Primary: Haemoglobin Level — 88.3; 89.2; 88.4; 89.6 g/L — p=<0.05
Phase 3 N=270 A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.
Haematopoiesis
Primary: Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily) — 2.6; 2.8 Gram per…
Phase 3 N=51 Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia
Anemia · Iron Deficiency Anemia
Primary: Feasibility of Enrolling Patients in the Trial — 85 participants
Phase 4 N=80 Comparison of NovaFerrum® vs Ferrous Sulfate Treatment in Young Children With Nutritional Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Hemoglobin Concentration Over Time — 7.7; 7.9; 9.3; 10.4 g/dL — p=<0.001
N/A N=809 Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?
Anemia · Iron Deficiency · Hemoglobin Disorder
Primary: Hemoglobin Levels at 12-weeks. Marginal Means (95% CI). — 123; 116; 121; 116 g/L — p=<0.05
Phase 3 N=7 Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044
Iron Deficiency Anemia
Primary: Change in Hemoglobin From Baseline to Day 35 — 0.70 g/dL — p=0.1711
Phase 4 N=1,000 Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes
Anemia · Diarrhea · Iron
Primary: Incidence of Diarrhea — 201; 204; 260; 224 episodes
Phase 4 N=38 Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial
Iron Deficiency Anemia of Pregnancy · Iron Malabsorption
Primary: Maternal Anemia at Delivery — 4; 11 Participants — p=0.039
Phase 4 N=20 Iron Bioavailability of Fortified Oat Drink
Iron Absorption
Primary: Percent Iron Absorption — 7.14; 5.65 percentage of Iron absorbed
N/A N=96 Chloroquine and Post Malaria Anaemia Study
Malaria Anaemia
Primary: Changes in Haemoglobin Concentration From Day 3 Post Treatment of Malaria Episode to Day 90 in the Weekly Chloroquine and Placebo Arms — 93.4; 93.7 g/L
Phase 4 N=13 Alternate Day Versus Daily Oral Iron Therapy in Adolescents
Iron Deficiency Anemia · Heavy Menstrual Bleeding · Abnormal Uterine Bleeding
Primary: Percentage of Eligible Patients Enrolled. — 13 Participants
Phase 1 N=37 Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency
Iron Deficiency, Anaemia in Children · Iron-Deficiency
Primary: Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 1 — 2.4518; 1.1632; 0.5299 mg/L
Phase 3 N=65 Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
Anemia · Iron-deficiency
Primary: Change in Hemoglobin Concentration — 17.7; 12.5; 11.5 g/L
Phase 3 N=100 Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients
Iron Overload
Primary: Occurrence of Adverse Events — 212 Adverse Events
Phase 3 N=150 Randomized Trial of Iron Supplementation to Prevent Anemia in Very-low-birth-weight Infants
Anemia
Primary: Hematocrit (Hct) — 29.2; 28.3 percentage of red blood cells in blood
N/A N=223 Effect of Iron/Zinc-Biofortified Pearl Millet on Growth and Immunity in Children Aged 12-18 Months in India
Iron Deficiency · Zinc Deficiency
Primary: Hemoglobin (g/dL) — 10.90; 10.30 g/dL
Phase 2 N=75 Probing the Synergistic Effect of Pre-Biotics & Iron Fortificants in Anemic Subjects
Iron-deficiency
Primary: Change in Hemoglobin Concentration From Baseline to 90 Days — 11.44; 11.58; 11.54; 11.61 g/dL
Phase 4 N=145 Safety and Efficacy of Iron Sucrose in Children
Anemia · Chronic Kidney Disease
Primary: Safety Profile: Number of Subjects Experiencing at Least 1 Adverse Event — 27; 25; 26 participants
N/A N=23 Feasibility or Oral Lactoferrin to Prevent Iron Deficiency Anemia in Obese Pregnancy
Iron-deficiency · Pregnancy Anemia · Obesity
Primary: Recruitment Feasibility — 10 percentage eligible and enrolled
Phase 2 N=34 Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease
Anemia of Chronic Kidney Disease
Primary: Change in Serum Hepcidin With Vitamin D Intervention for Children With Chronic Kidney Disease — 48.2; 75.4 ng/ml
N/A N=223 Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study
Iron-deficiency Anemia · Iron-deficiency
Primary: Haemoglobin Level — 11.35; 12.28 g/dL — p=0.025
Phase 4 N=64 Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
Beta Thalassemia Major Anemia · Iron Overload
Primary: The Percentage of Patients in Each Treatment Group Who Still Have a Serum Ferritin Level < 1000 Micrograms Per Liter (μg/L) at Month 12 — 21; 12 Participants — p=0.0446
N/A N=288 Prebiotic GOS and Lactoferrin With Iron Supplements
Iron-deficiency
Primary: Ratio of Harmful to Beneficial Bacterial Genera in Fecal Microbiota as Determined by Quantitative Polymerase Chain Reaction (qPCR) at 1 Month — 2.208; 1.530; 2.075…
N/A N=102 Iron Parameters in Non-anemic First Trimester Gravidas
Iron Deficiency (Without Anemia) · Pregnancy
Primary: Percent of Non-anemic Patients With Iron Deficiency Stratified by Gravidity — 9; 3; 6; 38 Participants
Phase 3 N=79 Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA
Iron Deficiency Anemia
Primary: Change in Hemoglobin g/dL — 2.22; 1.92 g/dL — p=0.3108
N/A N=25 Investigation of Iron Uptake From Micronutrient Fortified Powder Versus From Tailored Control in Milk
Growth and Development
Primary: Fractional Iron Absorption — 2.08; 1.25 % Iron Absorbed — p=0.0944